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OPTIMIZATION OF DELIVERY OF TGF-BETA FOR IMPROVING QUALITY 
OF ENGINEERED ARTICULAR CARTILAGE  
TIANBAI WANG 
ABSTRACT 
Osteoarthritis (OA) is a painful, debilitating condition that results from the mechanical 
degeneration of articular cartilage. Cartilage tissue engineering is a promising OA therapy, 
whereby chondrogenic cells are encapsulation in a hydrogel scaffold and cultivated in vitro 
in an attempt to create a suitable replacement tissue. Transforming growth factor-beta 
(TGF-b) is a highly anabolic hormone that has served as one of the most prominent 
cartilage growth mediators, promoting the development of engineered tissues with native 
levels of mechanical properties and biochemical contents. In cartilage tissue engineering, 
TGF-b is conventionally administered supplemented in culture medium with the 
expectation that it will readily diffuse into tissue constructs. However, recent evidence has 
brought to light severe limitations with this approach when attempting to generate 
engineered cartilage of sufficient size to repair clinical OA defects (10-25mm), as media-
supplemented TGF-b exhibits vast transport limitations in constructs, giving rise to 
undesirable, highly heterogeneous cartilage formation. Consequently, a long-term goal of 
our research group is to develop novel TGF-b chemical delivery strategies that achieve 
improved uniformity of its activity in the tissue. Critically, the development of these 
strategies require a fundamental understanding of the optimal delivery profile (exposure 
concentration and duration) of TGF-b activity to achieve optimal cartilage tissue growth. 
Interestingly, while low doses of TGF-b are typically associated with insufficient growth 
 vi 
and matrix deposition, supraphysiologic doses are associated with the induction of 
pathological tissue features, such as fibrosis, chondrocyte hypertrophy and the clustering 
of chondrocytes in a phenotype that does not resemble healthy articular chondrocytes. Here 
we perform this characterization by examining the effect of near physiologic doses (0.1-
1ng/mL) and supraphysiologic doses (3-100ng/mL) of TGF-b on constructs growth. 
Further, we exposed tissue constructs to varying temporal delivery profiles. Results 
demonstrate that, interestingly, physiologic TGF-b doses (0.1-1 ng/mL) induce the 
formation of engineered cartilage with native mechanical properties (350-780 kPa) but with 
improved tissue quality, as marked by more isolated chondrocytes that resemble the 
phenotype of native cartilage. These results pave the path for the future development of 
large sized engineered cartilage tissues, whereby, physiologic levels can be delivered 
uniformly throughout the tissue via biomaterial delivery strategies.  
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CHAPTER 1. Introduction 
Articular cartilage is a type of hyaline cartilage located in diarthrodial joints that 
provides lubrication during joints motion while withstanding large loads1. Osteoarthritis is 
a painful debilitating condition that results from the degradation of articular cartilage, 
leading to pain and movement limitation in individuals. In the United States, osteoarthritis 
(OA) is the most common cause of disability2. Cartilage tissue engineering is a promising 
treatment therapy to combat OA whereby chondrogenic cells are encapsulated in hydrogel 
scaffolds and cultivated in vitro to create a suitable replacement tissue3. A major challenge 
in the technique is creating engineered tissue with a mechanically robust extracellular 
matrix (ECM) that can exhibit long term survival upon implantation in the native synovial 
joint. 
In cartilage tissue engineering, the anabolic hormone, transforming growth factor-beta 
(TGF-b), has served as one of the most prominent cartilage growth mediators. TGF-b acts 
by binding to extracellular membrane receptors on chondrocytes and including high levels 
of secretion of cartilaginous ECM constituents, such as glycosaminoglycans (GAG), 
collagen, and other matrix proteins. Recent successes in the field have demonstrated that 
the supplementation of culture medium with TGF-b can induce formation of engineered 
cartilage with mechanical properties and biochemical contents that match those if native 
articular cartilage4-7.  
Interestingly, despite the clear importance of TGF-b activity on engineered cartilage 
growth, recent work has demonstrated critical limitations of the conventional delivery 




been shown that, contrary to conventional expectations, media supplemented TGF-b 
exhibits pronounced spatial concentration gradients in engineered tissues8 (Fig 1.1). These 
gradients give rise to engineered tissues with highly pronounced heterogeneities in ECM 
production8, whereby, while native biochemical content is produced at the media-exposed 
tissue periphery, the tissue central regions are ECM deficient. These heterogeneities are 
highly undesirable, giving rise to a tissue that is unlikely to exhibit long term survival upon 
implantation in the dynamic mechanical environment of the synovial joint.  
 
Fig 1.1 Finite element (FE) model of spatial TGF-b distribution in constructs. 
The initial TGF-b concentration in media bath was 10 ng/mL, after 72 hours, TGF-b in media was 
internalized and bound on construct, the model shows a sharp TGF-b concentration gradients, and 
limitation of penetration8. 
 
This transport limitation serves as a strong motivation for the utilization of alternative 




multitude of localized TGF-b strategies have been developed in recent years, they typically 
exhibit an initial burst delivery of highly supraphysiologic levels of TGF-b in the tissue9,10. 
However, these levels may not be optimal for high quality cartilage tissue formation. In 
previous studies, it’s discovered that fibrosis, chondrocyte hypertrophy and the clustering 
of chondrocytes, which are phenotypes in native pathological cartilage, are also found in 
engineered cartilage cultivated with supraphysiologic TGF-b doses (~10 ng/mL)8,11, 
indicating high doses of TGF-b may be associated with the induction of pathological tissue 
features. While the application of moderated, near-physiologic TGF-b levels (0.1-1 ng/mL) 
may serve as a preferred strategy, few desirable results were obtained by previous 
investigations.  
As the issues described above, it still remains unclear of the optimal delivery regimens 
that will achieve optimal tissue growth. Therefore, in this dissertation, we investigated the 
both the effects of doses and supplemented durations of TGF-b on engineered articular 
cartilage’s quality in mechanical, biochemical properties and cell morphologies to study 
the optimization of TGF-b delivery strategy to create optimal cartilage growth. 
1.1  Aims of Investigation 
 The goal of this investigation is to determine the optimal regimen of TGF-b 
activity exposure to achieve optimal growth of engineered cartilage. The first study of this 
work (Chapter 3) investigates the effect of varying doses of TGF-b on cartilage growth. 





1.2  Structure of Thesis 
Chapter 2 describes background information on articular cartilage and OA. In 
addition, this chapter introduces cartilage tissue engineering, whereby encapsulation of 
chondrogenetic cells in hydrogel scaffolds and is a promising therapy to OA. The chapter 
also includes the structure and function of TGF-b, which is one of the most general anabolic 
mediators applied in cartilage tissue engineering.  
In the following chapters, Chapter 3 details our investigations on near-physiologic 
TGF-b levels effect on engineered cartilage tissue’s mechanical and biochemical properties 
and tissue quality, Chapter 4 describes our study on time strategies to TGF-b 
supplementation and their effect on tissues properties. And finally, Chapter 5 summarizes 





 CHAPTER 2. Background 
 Millions of patients are suffering from joint disorders like osteoarthritis (OA) in 
the world, and this number is highly likely to increase resulting from the aggravating trend 
of ageing population12. In addition, OA is a major cause of movement disability and joints 
pain, threatening over 10% of population aged over 60 in the United States13. Therefore, 
understanding healthy articular cartilage and OA and investigating therapies that can be 
applied in clinic is one of the most challenging tasks in musculoskeletal field. 
2.1  The Composition and Structure of Articular Cartilage 
Articular cartilage is a type of hyaline cartilage that can bear high loads, for healthy 
articular cartilage, it has a smooth, glistening surface, serving as a lubricating part in 
diarthrodial joints1,14,15. However, unlike most tissues, articular cartilage is an avascular 
tissue, without blood, lymphatic vessels and nerves, it has a very limited regenerative 
capacity and difficulties to repair when experiencing damage and disease14-16. 
Generally, articular cartilage is composed primarily of interstitial water, 
proteoglycans (PG), collagens and chondrocytes (Fig 1.1)1,14-16, among them, water, PG 
and collagens compose the major part of extracellular matrix (ECM) in cartilage tissue, 
and chondrocyte is the only cell type located in articular cartilage1. Like many tissues, 
water is the richest component in articular cartilage, which takes approximately 70-85% of 
the wet weight. In addition, PG and collagens are the majorities of ECM, sharing 30% and 





Fig 2.1 Structure of diarthrodial joint (top left), and structure of articular cartilage in micro 
(bottom right), ultra (bottom center) and nano (bottom left) scales1. 
 
Proteoglycans (PGs) are macromolecules formed by a core protein and covalently 
bound glycosaminoglycans (GAG) chains1,14-17. In articular cartilage matrix, aggrecan is 
the most abundant kind of proteoglycans, and is also the hallmark of chondrogenesis1,. The 
aggrecans are able to link with hyaluronan noncovalently via link proteins, then form large 
aggregates, which contribute a lot to cartilage’s ability to resist compression (Fig 2.2)1. 
GAGs are linear polysaccharides, many types of GAG (e.g. keratan sulfate, chondroitin 
sulfate and heparan sulfate) are negatively charged, in result, positive ions in environment, 




addition, when cartilage is compressed, the negative sites on GAGs are pushed closer, 
raising the charge-charge repulsion force, then providing cartilage the ability to bear 
compressive loads1,15-18. 
 
Fig 2.2  Schematic diagrams of proteoglycans and proteoglycan aggregate. 
Proteoglycans (PG) are composed of a core protein and GAG attachments, forming a comb-like 
structure (left top), the PG aggregate on hyaluronic acid chain via link proteins to form proteoglycan 
aggregate17. 
 
Collagens are a superfamily of fibrous proteins that exist most abundantly in 
ECM16,19,  so far, over 19 different types of collagens have been identified1,19. Typically, 
collagens are defined by the large domains of repeating –Gly-X-Y- amino acids 
sequences19, the polypeptides form α chains in left-handed direction, then three α chains 
build up a right-handed triple helix (Fig 2.3)1,19. Collagens are classified by the components 




the most abundant collagen, forming networks mainly with type IX and XI collagens,1,14-
16,19-21 The collagen fibrils and framework enable cartilage to bear tensile loads and 
maintain the shape of cartilage1,16.  
 
Fig 2.3 Diagrams of collagens structures. 
The primary structure of collagen is an α chain in a sequence of –Gly-X-Y-, three α chains form a 
triple helix and develop to collagen fibril1. 
 
Articular cartilage is heterogeneous in composition and structure along with depth, 
collagen fibril orientation, PG networks and content, water portion and chondrocytes 
morphology all vary with regions1,14-16. Generally, articular cartilage is divided into four 
regions, as superficial zone, middle zone, deep zone and calcified cartilage (Fig 1.2)1,15,22. 
In superficial zone, collagen fibrils align in parallel to the cartilage surface, while in deep 
zone, they’re perpendicular to calcified cartilage periphery1,12-14. In addition, collagens are 






Fig 2.4 Schematic of arrangement of zones in articular cartilage.  
Articular cartilage is classified into four regions, including superficial, middle, deep zones and 
subchondral bone along with the distance to cartilage surface. Collagen fibrils are parallel to 
cartilage surface curve in superficial zone, forming network in the middle zone, and become 
perpendicular to the boundary between deep zone and subchondral bone in the deep zone14. 
 
2.2  Overview of Osteoarthritis 
Osteoarthritis (OA) is a joint disease that affects millions of people in the world, it 
usually happens in knees, hips and small hand joints, leading to pain and function loss23. 
Although OA is usually diagnosed by cartilage degradation, the pathogeny may be much 
more complicated. In osteoarthritic joints, many cytokines and cell types are involved, 





Fig 2.5  Comparison of healthy and osteoarthritis in bone and cartilage structure, cells and 
cytokines status. 
In osteoarthritis cartilage, macrophage is activated and cytokines are secreted mediators that brings 
to cartilage erosion, hypertrophic chondrocytes are formed rather than healthy chondrocyte, and 
osteoblast is activated, increasing bone turnover24. 
 
In early OA, superficial zone of articular cartilage is firstly affected and starts 
fibrosis1,14,22,25, a high content of PG form which cannot bound with hyaluronic acid are 
secreted, the non-aggregated form will shorten the length of PG, resulting in abnormal 
matrix formation26, loss of PG in ECM and mechanical degradation of cartilage (Fig 2.6), 
also leading to the decrease of stiffness of cartilage1,14,22. In addition, although the content 
of collagens is stable, the framework is remodeled in osteoarthritic cartilage1,14,22,25, 




loss and collagen network damage lead to osteoarthritic cartilage surface degeneration and 
disruption. 
 
Fig 2.6 Histology of PG in healthy and OA articular cartilages. 
Safranin O staining of healthy cartilage (left) and OA cartilage (right). The staining region 
represents PG distribution, which indicates PG loss in the superficial zone of OA cartilage14. 
 
2.3  Cartilage Tissue Engineering 
Tissue engineering is a technique involving isolated cells, tissue-inducing substances 
(e.g. growth factors, cytokines), constructs are cultivated in vitro to regenerate or remodel 
tissues for repair or replacement (Fig 2.7)27-29. Since articular cartilage’s special avascular 
structure, self-repair becomes challenging when it meets with injury or degradation1,3,12-14. 
Therefore, tissue engineering provides a biomimetic strategy for cartilage regeneration, 





Fig 2.7 Procedure of Tissue engineering. 
Tissue engineering technique includes three steps, cells are first isolated from tissue (left), then cell 
suspension is mixed with scaffold (usually hydrogel) to form engineered tissue constructs and 
cultivated in culture media (center), finally the engineered tissue is implanted into patients 
(bottom)28. 
 
In cartilage tissue engineering, cell, scaffold and cytokine types vary widely, and 
many strategies are proved to create native-level engineered cartilage in biomechanical and 
biochemical aspects4-7,13, which shows a promising potential of applying tissue engineering 
is OA treatment. For cells sources, chondrocytes, which is the only type of cell in articular 
cartilage, is widely applied in cartilage tissue engineering3,4,6,8,13,27, in addition, 
mesenchymal stem cells (MSC), which has ability of chondrogenic differentiation, is 




types, synthetic polymers and biologic materials33-35. Biomaterials, e.g. agarose, hyaluronic 
acid (HA) and collagens, are generally natural or natural-derived polymers, making it more 
friendly to cells, and cells tend to have a high affinity to attach on the scaffold to proliferate 
and produce ECM3,33-35. However, for most natural scaffolds, they’re not able to provide a 
stiff structure for the system, which affects cells fate deeply23. On the contrary, synthetic 
scaffold e.g. polyethylene glycol (PEG) and poly(lactide-co-glycolide) acid (PLGA) can 
form a stiff sponge structure, but cells have difficulties secreting matrix and even adhere 
on the scaffold, more modifications have to be done before the application3,33-35,36. 
Moreover, growth factors, e.g. TGF-b, insulin-like growth factor (IGF) and fibroblast 
growth factor (FGF), are powerful in regulation of cells proliferation, metabolism and 
ECM maintain3 and sine qua non in cartilage tissue engineering. 
2.4  TGF-b Utilization in Cartilage Tissue Engineering 
Transforming growth factor beta (TGF-b) is a superfamily of powerful mediators that 
can modulate the proliferation, differentiation of cells, and maintain the growth and 
degradation of tissues38. Three TGF-b isoforms (b1, b2, and b3) are secreted in inactive 
(latent) forms composed of active complex, latency associated peptide (LAP) and latent 
TGF-b binding proteins (LTBP) (Fig 2.8), and activated extracellularly39,40. In native 
cartilage, latent TGF-b is largely stored (about 300ng/mL)34, while active TGF-b content 





Fig 2.8 Formation and structures of active and latent TGF-b. 
Precursor is firstly made, composed of TGF-b dimer (25kDa) and LAP dimer (75kDa) (top), after 
proteolytic process, the precursor forms small latency complex (SLC) (center), further, SLC 
covalently binds with LTBP (180kDa), forms large latent complex (LLC) (bottom)37. 
 
Generally, TGF-b is delivered in cartilage tissue engineering in two strategies. One is 
an exogenous method that supplement TGF-b in culture media for a certain period4-8,11, the 
other is an immobilization strategy that conjugate TGF-b with scaffold9,10,41,42. For 
exogenous TGF-b supplementation, many concentrations and delivery strategies have been 
investigated in prior studies, and typically, supraphysiologic doses (≥10 ng/mL) are 
applied in researches4-8. It’s discovered that with 10 ng/mL TGF-b supplementation for 
only the initial two weeks, the mechanical and biochemical properties of constructs were 
as good as native articular cartilage, while constructs exposed to 10 ng/mL TGF-b for the 




study that for other lower TGF-b doses, similar phenomena happened that constructs with 
temporal TGF-b exposure were much stiffer than constructs with continuous TGF-b 
supplementation. Therefore, two-week of 10 ng/mL TGF-b exposure is widely used in 
general cartilage tissue engineering studies4,6,7,13,43.  
However, it seems that this strategy is still far from perfect to create large constructs 
that can be implanted in clinic8,11. It’s reported that exogenously supplemented TGF-b has 
limitations to penetrate into constructs as cells on periphery can internalize TGF-b 
rapidly11, bringing to pronounced concentration gradients along constructs depth no matter 
the initial doses are supraphysiologic (Fig 2.9, i, ii) or near-physiologic (Fig 2.9, iii). TGF-
b not only has diffusion difficulties, it also accumulates on scaffold periphery, making the 
TGF-b concentrations on the surface much higher than expected (Fig 2.9, ii, iii). 
 
Fig 2.9 Limited penetration of exogenously supplemented TGF-b in constructs. 
Concentration of localized TGF-b along with depth of construct with 0.1, 0.3 and 1 ng/mL TGF-b 
supplemented in media bath. TGF-b accumulated on constructs periphery and the concentration is 





In addition, the 10 ng/mL TGF-b supplementation and concentration gradients can 
lead to undesirable biomechanical heterogeneities and pathologic tissue growth8,11. The 
supraphysiologic TGF-b doses can lead to compromised tissue quality in the form of cell 
clusters (Fig 2.10, i, ii, and iv) and fibrotic tissue layers (Fig 2.10, iii), which may result 
from hypertrophy or excessive cell proliferation. These fibrotic and cell phenotype features 
are, interestingly, associated with OA progression11 and are, unsurprisingly, consistent with 
the response of native articular cartilage to excessive TGF-b activity. 
  
Fig 2.10 Supraphysiologic TGF-b levels compromise tissue engineered cartilage ECM quality. 
(i, ii, iv) Safranin O and calcein-AM imaging showing cell clusters and hypertrophic chondrocytes8, 
which are not present in healthy cartilage, and (iii) Immunostaining of tissue engineered construct 
showing surface fibrotic type-I collagen (dashed line= construct outline)11 
 
As exogenous TGF-b supplementation brings to heterogeneous ECM synthesis and 
pathologic tissue growth, immobilization delivery strategies were proposed to conjugate 
TGF-b with chemically-modified scaffolds9,10,41,42. Conjugated TGF-b has a uniform 





immobilized TGF-b delivery appears to be a promising tissue engineering strategy that can 
mitigate heterogeneous growth and may lead to the production of engineered cartilage 
constructs with uniform native mechanical and biochemical properties. 
Typically, the scaffolds in delivery system can be classified into hydrogel, solid and 
hybrid scaffolds10, and TGF-b is generally encapsulated directly or bio/chemically into 
scaffolds, or first encapsulated into microspheres or nanoparticle, then loaded into a 
scaffold base (Fig 2.11). For bio/chemical encapsulation, scaffolds are usually chemically 
modified to add on amine/thiol-reactive groups, then TGF-b is encapsulated into modified 
scaffolds e.g. acrylate/thiolated HA/agarose/PEG, alginate sulfate, etc.9,41,42,44,45. In 
addition, high affinity domains like heparin-binding domains or adsorption peptides are 
also applied in scaffolds modification10,62. Besides direct encapsulation, TGF-b can also be 
encapsulated into microspheres first, and incorporated into scaffolds. In prior studies, TGF-
b was examined to be coencapsulated into alginate, fibrin, gelation or PLGA microspheres 
with HA, gelatin or PEG scaffolds, and many of the results showed that TGF-b can 
successfully stimulate MSCs chondrogenic differentiation9,46-48. 
     
Fig 2.11 Schematic of TGF-b immobilized delivery strategies. 
Generally TGF-b is directly (left) or bio/chemically (middle) localized into scaffolds, or 




Although it’s reported that localized TGF-b still can enhance constructs mechanical 
and biochemical properties, and regulate chondrogenic differentiation of MSCs9,10,41,42,44,45, 
and many conjugation systems have been investigated so far, few studies investigated the 
optimal conjugated TGF-b doses, release rate and release dose, 10 ng/mL and approximate 





CHAPTER 3. Dose-Dependent Effects of TGF-b on Engineered Articular Cartilage 
Growth 
3.1  Introduction 
Generally, for engineered cartilage growth, cell-seeded constructs are exposed to 
supraphysiologic levels of TGF-b that far exceed the levels that chondrocytes are exposed 
in their native environment. While supraphysiologic TGF-b supplementation can induce 
the formation of cartilage with native mechanical and biochemical properties,4-7 
interestingly, it is further associated with the induction of pathological tissue features, such 
as fibrosis, chondrocyte hypertrophy and the clustering of chondrocytes, which resemble 
unhealthy articular cartilage, are observed in these supraphysiologic doses studies8,11. 
While, near-physiologic doses of TGF-b supplementation (~0.1-1 ng/mL) may achieve 
improved tissue growth, their effect on tissue growth has not previously been examined 
since they exhibit limited penetration into tissues of conventional sizes (5mm) (Fig). In this 
study, we investigated the dose dependent effect of media supplemented TGF-b on 
engineered cartilage growth. Doses include physiologic levels (0.1, 0.3, 1 ng/mL) and 
supraphysiologic levels (3, 10, 30, 100 ng/mL). In the first study, we investigated the 
effects of these doses on small (3mm) constructs where TGF-b gradients in the tissue are 
mitigated. In the second study of this investigation, we examined the effect of TGF-b doses 





3.2  Effect of Supra- and Near-Physiologic Doses of TGF-b on Small Engineered 
Cartilage Growth 
3.2.1  Materials and Methods 
Cell Isolation and Tissue Constructs Fabrication 
Chondrocytes were isolated from young (3-6 month-old) bovine cartilage according 
to former studies49. Briefly, cartilage was harvested from eight bovine carpometacarpal 
joints (Green Village Packing Co), and digested via collagenase at 4.5 mg/mL 
(Worthington Biochemical Corporation, Lakewood, NJ) at 37℃ for eight hours. Cells 
suspension was filtered and centrifuged at 1000×g for 15 minutes, and seeded in 2% 
agarose (Type VII, Sigma, St. Louis, MO) at density of 30×106 cells/mL. Tissue constructs 
(Æ3´2.3mm) were made by biopsy punches (Miltex, York, PA) after gelation. 
Tissue Cultivation 
Tissue constructs were cultivated at 37℃ in chondrogenic medium. Medium was 
replenished three times per week. Constructs were exposed to active TGF-b3 (R&D 
Systems) at a concentration of 0, 0.3, 1, 10, 30 or 100 ng/mL for only the initial two weeks, 
then maintained without TGF-b. Constructs were collected from culture after 28 days for 
mechanical and biochemical analyses. 
Mechanical Testing 
The compressive Young’s modulus (EY) of constructs was measured as described 
previously5,6. Briefly, constructs were subjected to unconfined compression in PBS via a 




rate of 1 µm/s, and 900s of relaxation was performed to reach equilibrium, compressive 
Young’s modulus was calculated by dimensions, equilibrium stress and applied strain.  
Biochemical Analysis 
After mechanical testing, constructs were weighed and digested by 0.5 mg/mL 
Proteinase-K at 56℃ for 16 h. Sulfated GAG (sGAG) content was measured from digested 
aliquots by 1,9-dimethylmethylene blue (DMMB) dye-binding assay and normalized by 
the wet weight of construct. 
Statistical Analyses 
One-way ANOVA was performed to evaluate the effects of supplemented TGF-b 
doses on mechanical and biochemical properties of constructs (Study 3.2), while two-way 
ANOVA is applied to determine the effects of TGF-b doses to both small and large 
constructs on mechanical properties and sGAG secretion (Study 3.3). Repeat experiments 
showed similar results, and p<0.05 is considered significant. 
3.2.2  Results 
Constructs Mechanical and Biochemical Properties 
In compressive Young’s modulus analysis (Fig 3.1), constructs exposed in near-
physiologic dose TGF-b (1 ng/mL) had no significant difference with 10 ng/mL constructs 
(227±6.7 kPa to 247±45.9 kPa, p=0.66), and with ≤10ng/mL TGF-b exposure, constructs 
were much stiffer than the ones without (control, 83± 11.5 kPa). However, when 
supplemented highly supraphysiologic doses (30 and 100 ng/mL), constructs stiffness 





Fig 3.1 Compressive Young’s modulus (EY) of constructs at day 28. 
Constructs were in Æ3´2.3mm, and cultivated in media with transient supplementation of 0, 0.3, 
1, 10, 30 and 100 ng/mL TGF-b3 for 14 days. Data represent the means and standard deviations of 
4-5 samples. 
 
For biochemical analysis, it was consistent with mechanical properties (Fig 3.2). Both 
1 and 10 ng/mL constructs reached a near-native level in sGAG content (4.28±0.125% and 
4.32±0.195%, respectively), and there was no significant difference between those two 
groups (p=0.59). Constructs exposed in 0.3 ng/mL also had a higher sGAG content 
(3.65±0.168%, p<0.01) comparing with control group (2.76±0.207%). Similar with 
mechanical testing result, constructs with 30 and 100 ng/mL TGF-b exposure had a lower 
sGAG content than ≤10ng/mL groups, and 100 ng/mL constructs had a close sGAG 





Fig 3.2 Sulfate GAG (sGAG) content (of wet weight) of Constructs at day 28. 
Constructs were in Æ3´2.3mm, and cultivated in media with transient supplementation of 0, 0.3, 
1, 10, 30 and 100 ng/mL TGF-b3 for 14 days. Data represent the means and standard deviations of 
4-5 samples. 
 
3.3  Supra- and Near-Physiological Doses of TGF-b Effect on Large and Small 
Sized Constructs 
3.3.1  Materials and Methods 
Tissue Constructs Fabrication and Cultivation 
Chondrocytes were harvested and isolated as described above (Part 3.2.1). Cells were 
seeded in 2% agarose (type VII) in 30×106/mL and punched into large (Æ5´2.3 mm) and 




Constructs in both sizes were cultivated in 0, 0.1, 0.3, 1, 3, 10 ng/mL active TGF-b3 
(R&D) exposure for first two weeks, then cultivated without TGF-b supple mentation. 
Constructs were collected from culture after 28 days for cell viability and morphology 
evaluation, and collected after 56 days for mechanical properties. 
Mechanical Testing 
Equilibrium compressive Young’s modulus was measured as Part 3.2.1. Briefly, 
constructs were performed in unconfined compression with 10% strain, equilibrium was 
reached after 900s relaxation, and compressive modulus was calculated from constructs 
dimensions, strain and equilibrium stress. 
Cell Viability and Morphology 
Small constructs were cut into thin sections (~100 µm) along vertical orientation, then 
processed by live/dead viability/cytotoxicity assay (Invitrogen) and imaged using confocal 
microscopy (Olympus) to evaluate cell viability and morphology. 
Statistical Analyses 
Two-way ANOVA is applied to determine the effects of TGF-b doses to both small 
and large constructs on mechanical properties and sGAG secretion. Repeat experiments 
showed similar results, and p<0.05 is considered significant. 
3.3.2  Results 
Constructs Mechanical Properties 
Near-physiologic dose of TGF-b (0.3 ng/mL) affected highly differently on small and 
large samples in mechanical properties. For small samples, constructs exposed in 0.3 




kPa), while for large samples with same dose of TGF-b exposure, it’s much softer than 
small constructs (264±20.8 kPa, p<0.01). In addition, for small samples, there’re no 
significant difference among 0.3-3 ng/mL exposure (~450 kPa), however, 3 ng/mL 
constructs were two times stiffer than 0.3 ng/mL samples in average modulus (579±106.8 
kPa to 264±20.8 kPa) in large group. 
 
Fig 3.3 Constructs compressive Young’s moduli (EY) at day 56. 
Two sized constructs’ compressive Young’s moduli were measured. Small constructs (Æ3mm) 
were represented by (a), and large samples (Æ5mm) were showed by (b). Data represent the means 
and standard deviations of 4-5 samples. 
 
Constructs Cell Viability and Morphology 
For live/dead images, green represented alive cells, while red dots represented dead 
cells. In both sized and all TGF-b doses groups, most cells were alive after 28 days culture 
(not all shown in thesis). Interestingly, though cells viability was similar among groups, 





without TGF-b supplementation, cells were almost in individual, similarly, 0.3 ng/mL 
constructs showed no clusters in morphology. However, in 1 ng/mL group, clustering cells 
become predominant, and with 3 ng/mL TGF-b exposure, nearly all cells were attached 
into clusters, which seems a pathologic growth of chondrocytes. 
 
Fig 3.4 Confocal images of constructs exposed in 0, 0.3, 1, 3 ng/mL TGF-b. 
Central regions of small constructs (Æ3mm) were observed, 20X magnification, 636×636 µm. 
 
3.4  Discussion 
In the first study by using smaller samples (Æ3mm) rather than conventional sized 
constructs (~Æ5mm), we discovered that both compressive modulus (Fig 3.1) and sGAG 
content (Fig 3.2) increased sharply when applying near-physiologic doses of TGF-b (0.3 
and 1 ng/mL), for 1 ng/mL construct, it has close levels of mechanical and biochemical 
properties to 10 ng/mL construct, which is the most popular level in cartilage tissue 
engineering study. This result hasn’t been shown in prior studies where larger samples 




of TGF-b is internalized by periphery cells immediately, and central cells have no chance 
to reach it, leading to TGF-b concentration gradients, and sacrifice of cartilage behavior; 
while for small samples, the TGF-b is allowed to have a more localized delivery, which 
can minimize the dose gradients and enhance constructs properties. 
What’s more, although 10 ng/mL construct has a good stiffness, highly supra-
physiologic TGF-b doses seem harmful to cells. With 14-day supplementation of 30 and 
100 ng/mL TGF-b, constructs were softer than the ones exposed in lower doses (Fig 3.1), 
and construct with 100 ng/mL TGF-b exposure was even softer than the one without TGF-
b. Biochemical results are similar to mechanical results. Sulfate GAG is one of the major 
components of aggrecan, which is the sign of chondrogenic ECM, and also an important 
contribution to compressive stiffness of tissue, low sGAG content in highly 
supraphysiologic TGF-b doses may represent they have a suppress effect on ECM 
secretion of chondrocytes, which may be the reason of low compressive moduli as well. 
Furthermore, the second study in this chapter provides a solid proof to the hypothesis 
in the first study, what’s more, it revealed the effect of TGF-b on tissues cell morphology, 
giving another view to evaluate the tissue quality and optimization of TGF-b doses in 
cartilage tissue engineering. 
In the second study, small and large sized constructs were exposed in a wide range of 
TGF-b doses including both supra- and near-physiologic levels. For small samples, near-
native mechanical properties were achieved from 0.3 ng/mL TGF-b supple-mentation, and 




However, for large samples, there’s a huge difference between 0.3 and 3 ng/mL, what’s 
more, 0.3 ng/mL constructs were much softer than native articular cartilage. This result 
provides a further proof that low TGF-b doses also have effects on tissue growth and/or 
ECM secretion to promote constructs behavior, but only because it has a limitation to 
penetrate into large constructs so that constructs properties are weakened. Compared to 
large samples, small constructs allow minimal concentration gradients, bring to apparent 
mechanical properties enhancement. 
In addition, the live/dead images show a cell morphology difference among low doses 
and high doses exposed constructs. As described above, clustering morphology seems a 
sign of pathologic tissue growth or chondrocyte hypertrophy. For higher doses 
supplemented constructs (1 and 3 ng/mL), though they have a native-level compressive 
modulus, clusters were observed in central region (Fig 3.4). On the contrast, for small 0.3 
ng/mL constructs, it not only has similar mechanical properties with native articular 
cartilage, but also maintains similar morphology with healthy cartilage tissue. This 
phenomenon represents that although there’s a wide range of TGF-b doses that can 
promote constructs mechanical properties to native level, it’s more strict to create tissue 
share similarity with healthy cartilage in cell morphology at the same time, and a moderated 
near-physiologic dose may serve as a preferable way to create engineered cartilage for both 





CHAPTER 4. Time-Dependent Effects of TGF-b on Engineered Articular Cartilage 
Growth 
4.1  Introduction 
TGF-b, which is one of the most powerful anabolic hormones, is widely utilized in 
cartilage tissue engineering studies for efficient ECM production and tissue growth. In 
many cases, TGF-b is exogenously supplemented in culture media to enhance stiffness and 
cellular biosynthesis5-8,11. However, recent findings have demonstrated that media-
supplemented soluble TGF-b is rapidly internalized by cells at the construct periphery, 
leading to pronounced and undesirable biochemical heterogeneities in the tissue8,11. What’s 
more, TGF-b is covalently bound with peptides or other reactive groups in bio/chemically 
modified scaffolds, e.g. maleimide, acrylate or thiolated HA, alginate, agarose or PEG to 
continuously deliver stable TGF-b doses41,42,45. Although the implementation of TGF-b 
conjugated scaffolds appears to be a promising tissue engineering strategy that can mitigate 
heterogeneous growth and may lead to the production of constructs with uniform native 
mechanical and biochemical properties, few studies have investigated the delivery duration 
optimization to create engineered cartilage in high quality. In this study, we investigated 
the time dependent effects of media supplemented TGF-b on engineered cartilage growth 
with three initial TGF-b doses (500, 100 and 10 ng/mL) and four temporal delivery 
strategies to examine the engineered cartilage growth dependence on TGF-b 
supplementation duration. In the future, these temporal delivery regimens can be 




4.2  Materials and Methods 
Tissue Constructs Fabrication and Cultivation 
Tissue constructs were created as detailed in Chapter 3. In brief, cartilage tissues were 
first harvested from young bovine forelimbs (Green Village), and digested via 4.5 mg/mL 
collagenase to get cells suspension. The cells were seeded in 2% agarose hydrogel at a 
30×106/mL cell density and cored into Æ4×2.0mm cylindrical constructs via biopsy punch 
after gelation. 
Tissue constructs were cultivated at 37℃ in chondrogenic medium4,8, with medium 
replenished three times per week. Constructs were exposed to varying TGF-b temporal 
exposure regimens, consisting of initial exposure concentrations of 500, 100 or 10 ng/mL, 
which decayed over time, according to profiles showing in Fig 4.1. Four different temporal 
delivery (TD) strategies were performed, labeled as TD1 toTD4, combining the initial 
TGF-b concentrations, constructs were named as “initial dose-delivery regimen”, e.g. 
TD500-1 represents constructs exposed in 500 ng/mL initial TGF-b supplemented media, 
and dose delivery changed followed TD1 shown in Fig 4.1 (a). The TGF-b exposure 
regimen for all groups was applied for the initial two weeks, and then constructs were 
maintained without TGF-b. An additional group of constructs were cultivated continuously 
in the absence of TGF-b exposure, serving as a control group. Constructs were collected 






Fig 4.1 Temporal delivery regimens of TGF-b supplementations with an initial TGF-b 
concentration of 500, 100 and 10 ng/mL. 
Exposure profiles decayed at varying rates over two weeks, giving rise to carrying temporal 
delivery regimens TD-1 to TD-4..  
 
Mechanical Testing 
The compressive Young’s modulus (EY) of constructs was measured as described in 

























































strain was performed in the rate of 1 µm/s, and 900s of relaxation was performed to reach 
equilibrium, compressive Young’s modulus was calculated by dimensions, equilibrium 
stress and applied strain.  
Biochemical Analysis 
Biochemical contents were analyzed as described in Chapter 3. In brief, after 
mechanical testing, constructs were weighed and digested via 0.5 mg/mL Proteinase-K. 
Sulfated GAG (sGAG) content was measured from digested solution by DMMB assay and 
normalized by the wet weight of constructs. 
Statistical Analyses 
Two-way ANOVA was performed to evaluate the effects of temporal delivery profiles 
and initial supplemented TGF-b doses on mechanical and biochemical properties of 
constructs. Repeat experiments showed similar results, and p<0.05 is considered 
significant.  
4.3  Results 
Mechanical testing results showed differences in four temporal delivery profiles along 
with the initial TGF-b doses (Fig 4.2). For 10 ng/mL TGF-b initial supplementation, 
interestingly, the four delivery regimens all induced similar enhancements of EY, and in 
average, all constructs achieved native mechanical properties level (~500 kPa). However, 
obvious differences among delivery profiles were discovered in constructs with higher 
initial TGF-b supplementation. For 500 ng/mL constructs, TD500-1 and TD500-2 
regimens yielded only EY only ~20 kPa, which are maintained near levels of pure agarose 




sharp enhancements in mechanical properties, reaching native cartilage levels. Similar 
results were observed for 100 ng/mL groups, with shorter delivery regimens increasing the 
final EY level. 
 
Fig 4.2 Compressive Young’s moduli of constructs at day 56. 
Initial dose represents the TGF-b concentration supplemented in the first culture day, and TD-1 to 
TD-4 represent the temporal delivery strategy profiles showed in Fig 4.1. * : p<0.05. 
 
Compared with mechanical testing results, biochemical results didn’t show much 
difference among groups. In 10 and 100 ng/mL groups, constructs with different delivery 
strategies exhibited similar sGAG contents (~5%), reaching native levels for all regimens. 






Fig 4.3 sGAG content (in wet weight) of constructs at day 56. 
 
4.4  Discussion 
Mechanical testing results showed an interesting phenomenon that delivery profiles 
can strongly affect constructs properties. For 10 ng/mL constructs, the compressive moduli 
among four temporal delivery groups were close to each other, showing that even a short 
duration of 10 ng/mL TGF-b supplementation ( ~ 2 days) can enhance constructs 
mechanical properties to native level (Fig 4.2).The temporal delivery regimen of two weeks 
continuous delivery at 10 n/mL, followed by TGF-b cessation (TD10-4), is the most 
commonly utilized delivery profile for media-supplemented TGF-b delivery in cartilage 
tissue engineering studies. Interestingly, groups TD10-1 to TD10-3 have a similar 




mechanical properties with fewer and shorter TGF-b supplementation. However, different 
mechanical testing results showed in 100 and 500 ng/mL construct. TD500-1 and TD500-
2 were extremely soft, which had similar stiffness with acellular agarose hydrogel, and 
TD500-3 construct’s stiffness was close to control group’s. On the contrary, TD500-4 
constructs, with only two-day 500 ng/mL TGF-b supplementation, were as stiff as native 
articular cartilage, possessing a much higher compressive modulus than TD500-1 to 
TD500-3 constructs. For 100 ng/mL groups, TD100-1 to TD100-3 groups showed a similar 
trend in mechanical properties with 500 ng/mL groups, which is less apparent than 500 
ng/mL groups. The results may represent that for extremely highly supraphysiologic TGF-
b doses, long-term supplementations in these levels will suppress expansion, or ECM 
production of chondrogenic cells or even be harmful to cells, leading to low mechanical 
properties, while only a short duration of TGF-b can intrigue cells proliferation or matric 
secretion, and the effect is strong enough to help cells regulate metabolism for a long period, 
bringing a native-level stiffness. On the other hand, moderated supraphysiologic TGF-b 
doses ( ~ 10 ng/mL) show different effects on constructs mechanical properties. 
Compressive moduli of constructs with four delivery strategies investigated in this study 
didn’t show differences with 10 ng/mL TGF-b initial supplementation. The reason of this 
result may be that a “shot” of TGF-b is enough for cells to expand, produce matrix and 
maintain tissue growth, while for a longer TGF-b exposure, the supplementation doesn’t 
hurt or destroy cells ability in ECM producing, thus, the cells are still capable to proliferate 
and secret ECM, creating stiff engineered tissue. 




in 100 and 500 ng/mL, the GAG contents among all groups were almost the same (Fig 4.3). 
Generally, negative charges in GAG can attract positive ions from environment, enhance 
tissues osmotic pressure, then provide cartilage compressive stiffness, and conventionally, 
GAG content is considered to be consistent with mechanical properties, however, in this 
study, the results show differently. For 500 ng/mL constructs, the modulus of TD500-1 or 
TD500-2 was only ~20 kPa, and TD500-4 constructs was nearly 35 times stiffer than 
TD500-1 and TD500-2, but the GAG contents of constructs in four temporal delivery 
strategies were not as that different as mechanical properties. In addition, constructs in 
10ng/mL groups were as stiff as native articular cartilage, and also have native-level GAG 
contents, while control constructs also had a close GAG percentage with only ~100 kPa 
in compressive modulus. The results may reveal a new view of correlation between 
constructs GAG content and compressive stiffness. As aggrecan in native articular cartilage 
has a comb-like structure with a core protein and GAG attachment, then bound with 
hyaluronan chain, the organization of aggrecan may be important in cartilage tissues 
mechanical properties. In addition, collagens providing networks to cartilage, which is 
significant in maintaining tissues shape and function, moreover, while hyaluronic acid, 
decorin and fibromodulin only take a small portion in cartilage composition, they may also 
be important in tissue structure development and maintain. Therefore, to evaluate the 
connection between mechanical and biochemical properties, GAG content is far from 
enough. We hypothesize that both the contents and arrangements of cartilage compositions 
are significant in the evaluation, and for this study, GAG, collagen, hyaluronic acid and 




find the reason that leads to the significant difference in mechanical properties among 
constructs in different temporal delivery profiles. 
As described in Chapter 3, supraphysiologic TGF-b doses may bring to pathologic 
tissue growth, though they can enhance tissues stiffness, and moderated near-physiologic 
doses may serve as the optimization delivery concentrations as long as TGF-b can penetrate 
constructs well, further studies can be investigated. First, cells morphology provides proofs 
to cells health condition, and evaluation if chondrogenic cells are experiencing pathologic 
growth or suspicious hypertrophy via clustering images, an additional cells morphology 
analysis is necessary for the evaluation of tissue quality and determination of optimization 
of TGF-b delivery strategies. What’s more, study with moderated TGF-b doses in different 
temporal delivery profiles is interesting to investigate, as Chapter 3 represents that low 
TGF-b doses can enhance tissues mechanical and biochemical properties without bringing 
potential pathologic tissue growth, the delivery strategies study will provide a further 
understanding to the TGF-b delivery optimization and pave the path to create large and 





CHAPTER 5. Conclusions 
This thesis demonstrates two studies investigating the optimization of TGF-b delivery 
regimen to create engineered articular cartilage in good quality via cartilage tissue 
engineering technique. In the first study, small (3mm) and large (5mm) constructs were 
exposed to a wide range of TGF-b temporal supplementation. The results described that 
within small constructs, where TGF-b gradients were minimized, moderated, near-
physiologic doses can enhance constructs mechanical and biochemical properties to match 
those in native articular cartilage, while the cell morphology is closer to healthy, native 
cartilage comparing to constructs exposed to supraphysiologic doses. In addition, low 
doses didn’t promote mechanical properties much in large constructs, indicating that TGF-
b penetration limitation may sacrifice constructs properties. In the second study, four 
temporal delivery regimens along with duration were performed to investigate the time 
dependent effects of TGF-b delivery on constructs properties, the results indicate that with 
highly supraphysiologic supplementation (100 and 500 ng/mL), delivery strategies affect 
a lot to constructs mechanical properties, and a shorter supplementation may be preferred, 
while for a lower supraphysiologic dose (10 ng/mL), four regimens didn’t show significant 
difference.  
For future studies, tissue quality of constructs with short-term supraphysiologic 
supplementations (TD500-4, TD100-4), which possessed high mechanical properties, need 
evaluated, e.g. cell morphology, collagen content, collagen type, PG and collagen 
distributions. Furthermore, moderated, near-physiologic doses supplementation with 




mechanical and biochemical properties, and tissue quality. Finally, with the “best” delivery 
regimens (for both doses and durations), TGF-b can be encapsulated into biomaterials to 
realize the delivery strategies uniformly, creating engineered articular cartilage in good 
quality, with native-level mechanical and biochemical properties, healthy cell morphology 
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